BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare
03 December 2019 - 11:52PM
·The Company partners with
Reified Capital, a provider of advanced artificial
intelligence-focused technical advisory services to the private
sector
·Collaboration to focus on
machine learning and artificial intelligence solutions for
healthcare
·Initial solutions to be
centered on BioSig’s core competencies in electrophysiology
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company entered into a technical
collaboration with Reified Capital, a provider of advanced
artificial intelligence-focused technical advisory services to the
private sector. Reified was co-founded by Dr. Alexander D.
Wissner-Gross and Timothy M. Sullivan, the founders of Gemedy.
The new collaboration with Cambridge, Massachusetts-based
Reified will focus on developing a foundational artificial
intelligence platform on the basis of integrated healthcare
datasets, beginning with ECG and EEG data acquired by BioSig’s
first product, PURE EP(tm) System - a novel real-time signal
processing platform engineered to provide electrophysiologists with
high fidelity cardiac signals. Electrophysiology focused
technological solutions developed under the terms of this
collaboration will be integrated into the PURE EP(tm) technology
platform. Reified is led by Harvard- and MIT-trained computer
scientist and physicist Dr. Wissner-Gross, an award-winning
computer scientist, physicist, entrepreneur and author. Technical
expertise that the Reified team is planning to bring to the project
includes data analysis, algorithmic modeling and development.
“Integration of AI can open new avenues for improved diagnosis
and more effective therapy delivery for bioelectronic medicine in
particular and healthcare in general. We are thrilled to partner
with Alex and his outstanding team, and look forward to working
with them on developing world-class artificial intelligence and
machine learning solutions, which, we believe, will benefit a
worldwide physician audience,” commented Kenneth L Londoner,
Chairman and CEO of BioSig Technologies, Inc.
“The application of modern AI and machine learning techniques to
electrophysiology presents one of the most promising healthcare
opportunities of our time,” said Dr. Wissner-Gross. “We look
forward to our forthcoming collaboration with BioSig Technologies.”
On November 21, 2019 the Company announced that it commenced
patient enrollment in its first clinical trial for the PURE EP(tm)
System.
About Reified Capital Reified Capital, LLC is a
provider of advanced artificial intelligence-focused technical
advisory services to the private sector. Reified’s areas of
expertise include machine learning, data analysis, modeling and
simulation, cybersecurity, knowledge management, cyber-physical
systems, and autonomous systems.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP(tm) System.
The technology has been developed to address an unmet need in a
large and growing market.The Company’s first product, PURE EP(tm)
System is a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory. The system is indicated for use under the
supervision of licensed healthcare practitioners who are
responsible for interpreting the data. This novel cardiac signal
acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during
electrophysiology procedures in patients with abnormal heart rates
and rhythms. BioSig’s ultimate goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and received FDA 510(k) clearance for the PURE EP(tm)
System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024